RA
Rafarma Pharmaceuticals, Inc.
RAFA · OTC
$0.04 -19.77% (-$0.01)
1M +9.65%
Market Cap $3.25M
P/E Ratio 9.30x
Div. Yield -
ROE 3.34%
Bulios Fair Price
$0.05
35.1% upside
Current Price
$0.037
Undervalued Fair Value Overvalued
According to Bulios Fair Price, RAFA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
100 /100
Cheap P/E 9.30x
EV/EBITDA 6.57x
P/S 0.35x
Growth
0 /100
Declining EPS growth 58.63%
Rev. growth 47.74%
Book val. growth 48.73%
Profitability
14 /100
Weak Gross margin 8.29%
Net margin 3.80%
Op. margin 5.33%
Quality
25 /100
Poor ROIC 3.80%
ROE 3.34%
ROA 2.91%
Debt
90 /100
Low Debt/Equity 0.00x
Current ratio 1.13x
Net debt/EBITDA -0.07x
Stability
45 /100
Moderate Beta 0.70x
Rev. volatility 46.30%
EPS volatility 65.85%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about RAFA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Sergey Brusnitsin
Employees
700
Headquarters
Sandy